Price Rises Return Akorn To Sales Growth
Continuing To Work Through Facility Compliance Issues
Raising prices for certain product lines helped Akorn to post its first sales growth since 2016 as the US injectables and ophthalmics firm worked towards addressing two FDA warning letters.
You may also be interested in...
Buried within its financial disclosure of a standstill agreement with creditors until 7 February, Akorn disclosed that it is considering whether to file for bankruptcy protection in the US.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.